Dr. Mark A. Varney, PhD., will present at the forthcoming 8th Neurodegenerative Conditions Research & Development meeting to be held September 18-19, 2014 in San Francisco, CA. The meeting is organized by Global Technology Community (GTC) and Dr. Varney has been invited in his capacity as Chief Executive Officer of Neurolixis to present in the session on Drug Mechanisms & Treatments in Parkinson's Disease.
His presentation is entitled "Targeting Serotonergic Receptors to Treat L-DOPA-Induced Dyskinesia (LID) in Parkinson’s Disease" and will take place at 9:20 AM on Thursday 18th September.
Neurolixis has established itself as a leader in the development of serotonergic drugs for LID, notably its clinical candidate NLX-112, which has received support from The Michael J Fox Foundation for Parkinson's research.
For full details of the GTC Bio conference see the meeting website.